Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure

Type 2 diabetes mellitus affects nearly 7% of the world’s population and is a significant contributor to the development of cardiovascular disease and heart failure. Historically, the pharmacologic therapy of cardiovascular disease has centered around blood pressure control, insulin and cholesterol...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dana Darwish, Pooja Kumar, Khushi Urs, Siddharth Dave
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Cells
Subjects:	SGLT-2 inhibitors heart failure diabetes mellitus cardiac biomarkers
Online Access:	https://www.mdpi.com/2073-4409/14/12/919
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta‐analysis
by: Patrick Savage, et al.
Published: (2024-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials
by: Ali Ibrahim Rahil, et al.
Published: (2025-05-01)

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence
by: Ruggero Mazzotta, et al.
Published: (2025-08-01)

Adipokines and Adipose Tissue: The Role and Use of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Patients with Diabetes or Heart Failure
by: Michalina Mazurkiewicz, et al.
Published: (2025-04-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study
by: Abdullahi Ahmed Mohamed, et al.
Published: (2025-08-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
by: Mehmet Birhan Yilmaz, et al.
Published: (2025-04-01)

Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling
by: Ioan-Alexandru Minciună, et al.
Published: (2024-08-01)

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
by: Abhishek Kansara, et al.
Published: (2022-09-01)

Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by: Ashley Wang, et al.
Published: (2025-03-01)

Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world
by: Minjung Bak, et al.
Published: (2024-12-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01)

Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives
by: V. V. Salukhov, et al.
Published: (2022-07-01)

2024 update in heart failure
by: Alberto Beghini, et al.
Published: (2025-02-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Effects of SGLT2 Inhibitors on Sleep Apnea Parameters and Cheyne–Stokes Respiration in Patients with Acute Decompensated Heart Failure: A Prospective Cohort Study
by: Petar Kalaydzhiev, et al.
Published: (2025-06-01)

Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
by: Iacob-Daniel Goje, et al.
Published: (2025-05-01)

Heart failure with preserved ejection fraction (HFpEF): phenotypes, diagnostic algorithms, and new therapeutic options
by: Arnold Péter Ráduly, et al.
Published: (2025-02-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

Pathogenetic aspects of the influence of gliflozins on erythropoiesis and iron metabolism in patients with chronic heart failure
by: R. A. Khachaturyan, et al.
Published: (2024-04-01)

Implications of Heart Failure Treatment on Atrial Fibrillation Onset: A Retrospective Study
by: Loredana Suhov, et al.
Published: (2025-02-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024-10-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

Clinical outcomes of pharmacological therapies for heart failure in Black vs. White populations: a meta-analysis of randomized controlled trials of heart failure treatment
by: Yujia Li, et al.
Published: (2025-06-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs
by: Huize Gao, et al.
Published: (2025-06-01)

Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
by: Francisco Epelde
Published: (2024-12-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-11-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review
by: George I. Lambrou, et al.
Published: (2025-04-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)